![Mary Tagliaferri](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mary Tagliaferri
Technik-/Wissenschafts-/F&E-Leiter bei
NEKTAR THERAPEUTICS
Vermögen: - $ am 31.10.2026
Profil
Dr. Mary A. Tagliaferri, MD, is an Independent Director at Iambic Therapeutics, Inc. and a Chief Medical Officer at Nektar Therapeutics.
She is on the Board of Directors at ADARx Pharmaceuticals, Inc. and Iambic Therapeutics, Inc. Dr. Tagliaferri was previously employed as an Independent Director by Y-mAbs Therapeutics, Inc., an Independent Director by Rayzebio, Inc., an Independent Director by Enzo Biochem, Inc., a Chief Medical Officer by Kanglaite USA, Inc., a President, Secretary, Treasurer & Director by Bionovo, Inc., and a Secretary, Treasurer & Chief Regulatory Officer by Lighten Up Enterprises International, Inc. She also served on the board at Atossa Therapeutics, Inc. She received her undergraduate degree from Cornell University, a graduate degree from Bryn Mawr College, a graduate degree from American College of Traditional Chinese Medicine and a doctorate degree from The University of California, San Francisco.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.10.2026 | 0 ( -.--% ) | - $ | 31.10.2026 |
Aktive Positionen von Mary Tagliaferri
| Unternehmen | Position | Beginn |
|---|---|---|
| NEKTAR THERAPEUTICS | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2025 |
| IAMBIC THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.08.2024 |
| ADARX PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.11.2025 |
Ehemalige bekannte Positionen von Mary Tagliaferri
| Unternehmen | Position | Ende |
|---|---|---|
| YMAS THER | Direktor/Vorstandsmitglied | 11.07.2025 |
| ENZO BIOCHEM, INC. | Vorsitzender | 25.10.2023 |
| RAYZEBIO, INC. | Direktor/Vorstandsmitglied | 26.02.2024 |
Kanglaite USA, Inc.
 Kanglaite USA, Inc. Pharmaceuticals: MajorHealth Technology The private company is based in Redwood City, CA. Kanglaite USA, Inc. is a biotechnology company developing treatments for solid tumors and cancer-associated anorexia-cachexia syndrome. The company’s lead product, Kanglaite Injection (KLTi), has been approved in China for the treatment of advanced non-small cell lung cancer and hepatocellular cancer, and is currently under investigation in the United States for cancer-related indications. The company focuses on discovering and developing natural therapies for various cancers, including pancreatic and prostate cancer. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2014 |
| BIONOVO INC. | Gründer | 01.06.2012 |
Ausbildung von Mary Tagliaferri
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
92
Beziehungen ersten Grades
14
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 14 |
|---|---|
Enzo Biochem, Inc.
 Enzo Biochem, Inc. BiotechnologyHealth Technology Provides enabling life science technologies for research, drug discovery, drug development and diagnostic solutions | Health Technology |
Nektar Therapeutics
 Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
Lighten Up Enterprises International, Inc.
 Lighten Up Enterprises International, Inc. Financial ConglomeratesFinance Development stage company | Finance |
Bionovo, Inc.
 Bionovo, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals & drugs | Health Technology |
Atossa Therapeutics, Inc.
 Atossa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics and delivery methods for the treatment of breast cancer & other breast conditions | Health Technology |
Bryn Mawr College
 Bryn Mawr College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American College of Traditional Chinese Medicine
 American College of Traditional Chinese Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Y-mAbs Therapeutics, Inc.
 Y-mAbs Therapeutics, Inc. BiotechnologyHealth Technology Develops radioimmunotherapy and antibody-based oncology therapies for treating cancer | Health Technology |
Kanglaite USA, Inc.
Kanglaite USA, Inc. Pharmaceuticals: MajorHealth Technology The private company is based in Redwood City, CA. Kanglaite USA, Inc. is a biotechnology company developing treatments for solid tumors and cancer-associated anorexia-cachexia syndrome. The company’s lead product, Kanglaite Injection (KLTi), has been approved in China for the treatment of advanced non-small cell lung cancer and hepatocellular cancer, and is currently under investigation in the United States for cancer-related indications. The company focuses on discovering and developing natural therapies for various cancers, including pancreatic and prostate cancer. | Health Technology |
ADARx Pharmaceuticals, Inc.
 ADARx Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops siRNA therapeutics to treat diseases | Health Technology |
Rayzebio, Inc.
 Rayzebio, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapeutics for cancer treatment | Health Technology |
Entos, Inc.
 Entos, Inc. BiotechnologyHealth Technology Operates as a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform | Health Technology |
